---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-082002"
form_type: "8-K"
ticker: null
cik: "0001796129"
company_name: "Vincerx Pharma, Inc."
filed_at: "2024-03-29T23:59:59+00:00"
generated_at: "2026-06-04T05:29:37.079850+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vincerx Pharma FY2023 net loss $40.2M; cash $12.8M, runway into early Q3 2024

## Summary
- Net loss for FY2023: $40.2M ($1.89/share) vs $63.0M ($3.00/share) in FY2022; Q4 2023 loss $4.9M ($0.23/share).
- Cash and equivalents $12.8M as of Dec 31, 2023, down from $52.5M year-end 2022; expects runway into early Q3 2024.
- R&D expenses fell to $29.0M in FY2023 from $49.8M in FY2022; G&A down to $13.6M from $18.9M.
- Pipeline: VIP236 Phase 1 dose-escalation ongoing with 20 patients; VIP943 Phase 1 enrolling third cohort (9 patients dosed).
- Enitociclib (CDK9 inhibitor) showed partial responses in PTCL and DLBCL combination studies with NIH.

## SEC filing metadata
- accession: 0001193125-24-082002
- form_type: 8-K
- cik: 0001796129
- company_name: Vincerx Pharma, Inc.
- filed_at: 2024-03-29T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1796129/000119312524082002/0001193125-24-082002-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1796129/000119312524082002/d743689d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-082002
- JSON: https://secwatch.observer/filing/0001193125-24-082002.json
- Plain text: https://secwatch.observer/filing/0001193125-24-082002.txt

## Key facts
- Earnings Releases
  Vincerx Pharma, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.
  - Period: the fourth quarter and full year ended December 31, 2023
  - Result: reported results
  source text: On March 29, 2024, Vincerx Pharma, Inc. (the “Company”) issued a press release announcing financial results for its fiscal year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1796129/000119312524082002/0001193125-24-082002-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.